Japanese artificial intelligence system diagnoses colorectal cancer in 0.3 seconds

Share This Post

Japanese researchers have developed an artificial intelligence system that extends an endoscope with a magnification of 500 times into the patient ‘s intestine. The artificial intelligence system can identify whether there is malignant change in the large intestine polyp in the endoscope within 0.3 seconds, according to real-time judgment results The doctor can decide whether to operate in real time.

Compared with the past, it takes a week to make a diagnosis, and now the system can immediately determine whether to remove it, which greatly improves the efficiency of diagnosis and treatment. During the development of this system, more than 60,000 tumor cell pictures were used to build a database. These pictures came from more than 3,000 patients with colorectal cancer diagnosed in 5 hospitals in Japan. By analyzing and deep learning the tumor images in the image database, the system has learned the automatic recognition function of cancer. Not only improve the diagnosis efficiency, but also improve the accuracy.

In Japan, colorectal cancer is the second most malignant tumor after death from lung cancer. Early detection is the key to improving the level of treatment. This artificial intelligence achievement in Japan can detect the presence of cancer in large intestine polyps in less than a second. At present, this artificial intelligence colorectal cancer diagnostic system has been clinically tested in 6 hospitals in Japan, and is expected to obtain the license from the relevant Japanese pharmaceutical regulatory authorities in 2018. 

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Targeting FGFR4 and CD276 with CAR T-cells demonstrates a strong antitumor impact against children rhabdomyosarcoma
CAR T-Cell therapy

Targeting FGFR4 and CD276 with CAR T-cells demonstrates a strong antitumor impact against children rhabdomyosarcoma

Chimeric antigen receptor (CAR) T-cells that specifically target Fibroblast Growth Factor Receptor 4 (FGFR4), a surface tyrosine receptor that is extensively expressed in rhabdomyosarcoma (RMS), are now undergoing clinical research. However, the effectiveness of these CAR T-cells may be hindered by tumor heterogeneity and inadequate activation. In this study, we present a method to enhance the co-stimulatory and targeting characteristics of a FGFR4 CAR through an optimization process. We substituted the hinge and transmembrane domain of CD8 as well as the 4-1BB co-stimulatory domain with the corresponding domains of CD28. The CARs produced exhibit heightened anti-tumor efficacy in multiple RMS xenograft models, with the exception of the RMS559 cell line, which is known for its aggressive nature.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, Gene therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) CAR T-Cell therapy
2) Gene therapy
3) Gamma-Delta T Cell therapy
4) TIL therapy
5) NK Cell therapy